Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeff Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer Conference Call Participants Francois Brisebois - Oppenheimer Charles Duncan - Cantor Fitzgerald Ami Fadia - Needham David Amsellem - Piper S ...

Tara Living with narcolepsy Taking WAKIX since 2020 Q2 2024 Financial Results August 6, 2024 Forward-Looking Statements 2 This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for ...

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 600%. A quarter ago, it was expected that this company would post earnings of $0.64 per share when it actually produced earnings of $0.67, delivering a surprise of 4.69%. Over the last ...

Exhibit 99.1 HARMONY BIOSCIENCES REPORTS STRONG SECOND QUARTER 2024 FINANCIAL RESULTS AND ADVANCES PITOLISANT HIGH-DOSE PROGRAM TOWARD EXPECTED PDUFA DATE IN 2028 WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Is ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |---------------------------------------------------------------------------------------------------------------------|----- ...

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment o ...

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment o ...

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic poss ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Harmony Biosciences Holdings, Inc. has a Zacks Rank of #2 (Buy), while Regeneron has a Zacks Rank of #4 (Sell) right now. Investors should feel comfortable knowing that HRMY likely has seen a stronger improvement to its earnings outlook ...

Shares of Harmony Biosciences Holdings, Inc. (HRMY) have gained 13.4% over the past four weeks to close the last trading session at $32.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $43.38 indicates a potential upside of 32.8%. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wi ...